Mutations that result in loss of ARID1A have been shown to contribute to faster tumorigenesis, progression towards metastasis, and development of chemoresistance across several cancers including ovarian, colon, osteosarcoma, and esophageal cancer [2,3,4,5,6,7,8,9]. This evidence concerns the gene ARID1A and cancer.